Drug Trial Radar · NCT06333860
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)
Last checked: Nov 20, 2026Latest source record: Apr 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
393
Actual
Start
May 10, 2024
Primary completion
Mar 19, 2026
Study completion Mar 19, 2026
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Mar 27, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Psoriasis is a long-term skin disease which causes red, itchy, scaly patches most commonly on the knees, elbows, scalp, and torso (chest, back, and abdomen). In participants with psoriasis, certain skin cells multiply much faster and the skin can develop rough patches that may be red or white with scales. There are many types of psoriasis, but plaque psoriasis is the most common. The exact cause of psoriasis is unknown, but researchers think it may be caused by the body's immune system not working properly. This study is designed to enroll 336 participants 18 years of age and older with have been diagnosed with moderate chronic plaque psoriasis for at least 6 months prior to Baseline (Day 1) and who have not previously been treated with a biologic treatment (natural substance that is made by using living cells in a laboratory). This is a Phase 4, randomized, open-label, assessor blinded, active comparator study with 2 Parts. Phase 4 studies test treatments that have already been approved to treat patients with a condition or disease. This study is open-label, which means that both participants and study doctors know which study treatment is given to participants Participants will be administered subcutaneous (SC) treatment of risankizumab every 12 weeks for up to 44 weeks or provided deucravacitinib oral tablets to be taken once daily. There may be higher treatment burden for participants in this trial compared to their standard of care (due to study procedures). Participants will attend regular (weekly, monthly) visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Conditions
- Moderate Plaque Psoriasis
Interventions
RisankizumabDrug
Solution for Subcutaneous (SC) injection
DeucravacitinibDrug
Oral tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Period A: Percentage of Participants Achieving 90% Improvement in Psoriasis Area Severity Index (PASI) Score (PASI 90)Time frame: At Week 16
- Period A: Percentage of Participants Achieving a Static Physician Global Assessment (sPGA) Score of 0 (Clear) or 1 (Almost Clear) with at least 2-grade improvement from BaselineTime frame: Baseline, Week 16
- Period B: Percentage of Participants Achieving 90% Improvement in Psoriasis Area Severity Index (PASI) Score (PASI 90) in the Intent to Treat Population for non-responders in Period B (ITT_B_NR).Time frame: At Week 52
- Number of Participants Experiencing Adverse Events (AEs)Time frame: Baseline up to 73 Weeks
Locations
88 sites in 12 countries. Site status is shown where the registry gives one.
Total Skin and Beauty Dermatology Center /ID# 263011
Birmingham, Alabama
Advanced Research Associates - Glendale /ID# 263621
Glendale, Arizona
Clear Dermatology & Aesthetics Center /ID# 263626
Scottsdale, Arizona
Dermatology Trial Associates /ID# 264480
Bryant, Arkansas
First OC Dermatology /ID# 263003
Fountain Valley, California
Integrative Skin Science and Research /ID# 264504
Sacramento, California
Physioseq, LLC /ID# 265035
Sacramento, California
Medderm Associates Dermatology /ID# 263858
San Diego, California
Southern California Dermatology /ID# 263021
Santa Ana, California
Clearlyderm Dermatology - West Boca /ID# 264963
Boca Raton, Florida
Driven Research /ID# 263002
Coral Gables, Florida
Skin Care Research - Hollywood /ID# 263877
Hollywood, Florida
International Dermatology Research /ID# 264911
Miami, Florida
Lenus Research and Medical Group /ID# 263886
Miami, Florida
Wellness Clinical Research - Miami Lakes /ID# 263887
Miami Lakes, Florida
Skin Care Research - Tampa /ID# 263880
Tampa, Florida
Advanced Clinical Research Institute /ID# 263878
Tampa, Florida
University Dermatology and Vein Clinic, LLC /ID# 263028
Chicago, Illinois
Arlington Dermatology /ID# 263001
Rolling Meadows, Illinois
Dawes Fretzin, LLC /ID# 264578
Indianapolis, Indiana
MetroBoston Clinical Partners /ID# 263860
Boston, Massachusetts
University of Michigan Health System - Ann Arbor /ID# 265233
Ann Arbor, Michigan
Clinical Research Institute of Michigan - Clinton Township Office /ID# 264968
Clinton Township, Michigan
Dermatology and Skin Center of Lees Summit /ID# 263560
Lee's Summit, Missouri
Physician Research Collaboration, LLC /ID# 263568
Lincoln, Nebraska
Skin Cancer and Dermatology Institute - Reno /ID# 263697
Reno, Nevada
StracSkin, PLLC /ID# 263024
Portsmouth, New Hampshire
Oregon Dermatology & Research Center /ID# 263674
Portland, Oregon
Clinical Partners /ID# 263862
Johnston, Rhode Island
Health Concepts /ID# 263016
Rapid City, South Dakota
Arlington Research Center, Inc /ID# 263908
Arlington, Texas
Bellaire Dermatology Associates /ID# 263897
Bellaire, Texas
U.S. Dermatology Partners - Cedar Park /ID# 263906
Cedar Park, Texas
Dermatology Treatment and Research Center /ID# 267071
Dallas, Texas
Texas Dermatology Research Center /ID# 264487
Plano, Texas
Dermatology Clinical Research Center of San Antonio /ID# 263869
San Antonio, Texas
Center for Clinical Studies - Clear Lake /ID# 263009
Webster, Texas
Center for Clinical Studies - Clear Lake /ID# 263917
Webster, Texas
Premier Clinical Research /ID# 263679
Spokane, Washington
Paratus Clinical Research Woden /ID# 263120
Phillip, Australian Capital Territory, Australia
Showing 40 of 88 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.